Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)
-
Narrated by:
-
By:
About this listen
ARDS, which is characterized by hypoxemic respiratory failure and inflammatory injury to the lungs, has a mortality rate of 30% to 40%. Balasubramanian Venkatesh, MD, of the George Institute for Global Health joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the effects of inhaled sedation with sevoflurane for patients with moderate to severe ARDS.
Related Content:
- Sevoflurane Sedation in Acute Respiratory Distress Syndrome
- Inhaled Sedation in Acute Respiratory Distress Syndrome
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet